Italy's Berlusconi recovering in 'optimal, convincing' way

By AP News


Former Italian Premier Silvio Berlusconi is now stable after three weeks in the hospital being treated for a lung infection

Italy Berlusconi

ROME (AP) — Former Italian Premier Silvio Berlusconi, who has leukemia, is now stable after three weeks in the hospital being treated for a lung infection, his doctors reported Wednesday.

Berlusconi, who was initially admitted to the intensive care unit of Milan’s San Raffaele clinic, has responded well to treatment in recent days with his lungs recovering in an “optimal and convincing” way, Drs. Alberto Zangrillo and Fabio Ciceri said.

Berlusconi, 86, was hospitalized on April 5 for a lung infection. During his hospitalization, his doctors revealed publicly for the first time that the former three-time premier and media mogul has chronic leukemia.

He was moved out of the ICU and onto a regular ward April 16.

In past years, Berlusconi has also suffered serious heart problems, and in 2020 was admitted to the same hospital, in critical condition, for treatment of COVID-19.

Members of Berlusconi’s Forza Italia party have expressed hope in recent days that he might be well enough to participate, either in person or remotely, at a big party rally on May 5-6 in Milan.

Forza Italia, which Berlusconi created in the 1990s, is a junior partner in the right-wing government of Premier Giorgia Meloni.


Author: AP News

This article does not provide any financial advice and is not a recommendation to deal in any securities or product. Investments may fall in value and an investor may lose some or all of their investment. Past performance is not an indicator of future performance.

Originally published by Associated Press, Digitonic Ltd (and our owners, directors, officers, managers, employees, affiliates, agents and assigns) are not responsible for the content or accuracy of this article. The information included in this article is based solely on information provided by the company or companies mentioned above.

Sign up for Investing Intel Newsletter